PE20151652A1 - Proceso e intermedios para preparar un medicamento - Google Patents
Proceso e intermedios para preparar un medicamentoInfo
- Publication number
- PE20151652A1 PE20151652A1 PE2015001956A PE2015001956A PE20151652A1 PE 20151652 A1 PE20151652 A1 PE 20151652A1 PE 2015001956 A PE2015001956 A PE 2015001956A PE 2015001956 A PE2015001956 A PE 2015001956A PE 20151652 A1 PE20151652 A1 PE 20151652A1
- Authority
- PE
- Peru
- Prior art keywords
- intermediates
- prepare
- medicinal product
- preparing
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Se divulga un proceso para preparar los siguientes compuestos (I) y (II): donde R1, R1a y R2a son como se han definido en la memoria descriptiva, asi como tambien un proceso para preparar otros intermedios que pueden ser utiles para sintetizar productos posteriores, especialmente compuestos que son utiles como medicamentos, por ejemplo, inhibidores de la tirosina-cinasa de Bruton (Btk) tal como ibrutinib. Tambien se divulgan otros procesos, otros intermedios compuestos per se
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361786842P | 2013-03-15 | 2013-03-15 | |
EP13159470 | 2013-03-15 | ||
EP13197813 | 2013-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20151652A1 true PE20151652A1 (es) | 2015-11-12 |
Family
ID=51535892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015001956A PE20151652A1 (es) | 2013-03-15 | 2014-03-11 | Proceso e intermedios para preparar un medicamento |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP2970291B1 (es) |
JP (1) | JP6777398B2 (es) |
KR (2) | KR102377688B1 (es) |
CN (2) | CN105026400A (es) |
AU (2) | AU2014230935A1 (es) |
BR (1) | BR112015021856A2 (es) |
CA (1) | CA2901510C (es) |
DK (1) | DK2970291T3 (es) |
EA (1) | EA201591685A1 (es) |
ES (1) | ES2924193T3 (es) |
HR (1) | HRP20220628T1 (es) |
HU (1) | HUE058914T2 (es) |
LT (1) | LT2970291T (es) |
MX (2) | MX2015012731A (es) |
MY (1) | MY194905A (es) |
PE (1) | PE20151652A1 (es) |
SG (2) | SG10201809696UA (es) |
SI (1) | SI2970291T1 (es) |
WO (1) | WO2014139970A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014004971B1 (pt) | 2011-09-02 | 2021-02-09 | Incyte Holdings Corporation | compostos heterociclilaminas, sua composição farmacêutica e seus usos |
CN105884747B (zh) * | 2014-08-28 | 2021-01-05 | 首药控股(北京)有限公司 | 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法 |
CN104447761A (zh) * | 2014-11-27 | 2015-03-25 | 广东东阳光药业有限公司 | 一种吡唑衍生物的制备方法 |
EP3248979B1 (en) * | 2015-01-21 | 2021-04-14 | Hefei Institutes of Physical Science, Chinese Academy of Sciences | Novel inhibitor of flt3 kinase and use thereof |
CN105481862B (zh) * | 2015-01-21 | 2018-08-21 | 中国科学院合肥物质科学研究院 | Flt3激酶的新型抑制剂及其用途 |
SI3831833T1 (sl) * | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
LV15201B (lv) * | 2015-08-31 | 2017-07-20 | Latvijas Organiskās Sintēzes Institūts | Ibrutiniba izejvielas iegūšanas paņēmiens |
CN106608877B (zh) * | 2015-10-21 | 2018-11-13 | 新发药业有限公司 | 一种依鲁替尼中间体4-氨基-3-(4-苯氧基)苯基-1H-吡唑并[3,4-d]嘧啶的制备方法 |
JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
WO2018103058A1 (en) * | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
WO2018145280A1 (zh) * | 2017-02-09 | 2018-08-16 | 合肥合源药业有限公司 | Flt3激酶抑制剂或其盐的晶型及其制备方法 |
CN107383017B (zh) * | 2017-07-20 | 2020-01-14 | 河南师范大学 | 依鲁替尼高效制备方法 |
EP3661939B1 (en) * | 2017-08-01 | 2021-07-21 | Boehringer Ingelheim International GmbH | Intermediate compounds and methods |
MX2021014245A (es) | 2019-05-21 | 2022-01-06 | Janssen Pharmaceutica Nv | Procedimientos y productos intermedios para preparar un inhibidor de btk. |
KR20220011668A (ko) | 2019-05-21 | 2022-01-28 | 얀센 파마슈티카 엔.브이. | Btk 억제제 제조를 위한 방법 및 중간체 |
CN113200987A (zh) * | 2021-04-29 | 2021-08-03 | 湖南华腾制药有限公司 | 一种伊布替尼的制备方法 |
CN115322226B (zh) * | 2022-08-17 | 2023-08-11 | 厦门大学 | 一种共价靶向砷抑制剂及其制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1212327T3 (da) * | 1999-09-17 | 2003-12-15 | Abbott Gmbh & Co Kg | Pyrazolopyrimidiner som terapeutiske midler |
KR101315610B1 (ko) * | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
CA2668286C (en) * | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
CA2874756C (en) * | 2007-03-28 | 2018-05-29 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
SI2414363T1 (sl) | 2009-03-31 | 2014-04-30 | Boehringer Ingelheim Gmbh | Derivati 1-heterociklil-1,5-dihidro-pirazolo/3,4-d/pirimidin-4-ona in njihova uporaba kot modulatorji za PDE9A |
US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
AU2011276955B2 (en) * | 2010-07-09 | 2014-11-06 | The Walter And Eliza Hall Institute Of Medical Research | Protein kinase inhibitors and methods of treatment |
EP2632898A4 (en) * | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | HETEROCYCLIC TYROSINE KINASE HEMMER |
US9376438B2 (en) * | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
KR20140048968A (ko) * | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
EP2882741B1 (en) * | 2012-08-10 | 2018-10-24 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
US20150291554A1 (en) * | 2012-11-02 | 2015-10-15 | Pfizer Inc. | Bruton's Tyrosine Kinase Inhibitors |
CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
-
2014
- 2014-03-11 MY MYPI2015002280A patent/MY194905A/en unknown
- 2014-03-11 PE PE2015001956A patent/PE20151652A1/es unknown
- 2014-03-11 KR KR1020217031854A patent/KR102377688B1/ko active IP Right Grant
- 2014-03-11 HR HRP20220628TT patent/HRP20220628T1/hr unknown
- 2014-03-11 HU HUE14708885A patent/HUE058914T2/hu unknown
- 2014-03-11 ES ES14708885T patent/ES2924193T3/es active Active
- 2014-03-11 CA CA2901510A patent/CA2901510C/en active Active
- 2014-03-11 CN CN201480015131.5A patent/CN105026400A/zh active Pending
- 2014-03-11 JP JP2015562078A patent/JP6777398B2/ja active Active
- 2014-03-11 SI SI201431956T patent/SI2970291T1/sl unknown
- 2014-03-11 KR KR1020157025525A patent/KR102311329B1/ko active IP Right Grant
- 2014-03-11 LT LTEPPCT/EP2014/054621T patent/LT2970291T/lt unknown
- 2014-03-11 SG SG10201809696UA patent/SG10201809696UA/en unknown
- 2014-03-11 SG SG11201507595XA patent/SG11201507595XA/en unknown
- 2014-03-11 DK DK14708885.0T patent/DK2970291T3/da active
- 2014-03-11 EP EP14708885.0A patent/EP2970291B1/en active Active
- 2014-03-11 EA EA201591685A patent/EA201591685A1/ru unknown
- 2014-03-11 AU AU2014230935A patent/AU2014230935A1/en not_active Abandoned
- 2014-03-11 WO PCT/EP2014/054621 patent/WO2014139970A1/en active Application Filing
- 2014-03-11 CN CN202011305518.8A patent/CN112608298A/zh active Pending
- 2014-03-11 MX MX2015012731A patent/MX2015012731A/es unknown
- 2014-03-11 BR BR112015021856A patent/BR112015021856A2/pt not_active Application Discontinuation
-
2015
- 2015-09-14 MX MX2020012596A patent/MX2020012596A/es unknown
-
2018
- 2018-06-08 AU AU2018204086A patent/AU2018204086B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016510779A (ja) | 2016-04-11 |
KR20210123429A (ko) | 2021-10-13 |
LT2970291T (lt) | 2022-06-10 |
MX2015012731A (es) | 2016-02-18 |
HUE058914T2 (hu) | 2022-09-28 |
CN112608298A (zh) | 2021-04-06 |
AU2018204086A1 (en) | 2018-06-28 |
CN105026400A (zh) | 2015-11-04 |
EA201591685A1 (ru) | 2016-01-29 |
WO2014139970A1 (en) | 2014-09-18 |
AU2018204086B2 (en) | 2020-03-12 |
MY194905A (en) | 2022-12-22 |
MX2020012596A (es) | 2021-02-09 |
BR112015021856A2 (pt) | 2017-07-18 |
JP6777398B2 (ja) | 2020-10-28 |
AU2014230935A1 (en) | 2015-09-03 |
DK2970291T3 (da) | 2022-08-01 |
KR102377688B1 (ko) | 2022-03-22 |
EP2970291A1 (en) | 2016-01-20 |
KR102311329B1 (ko) | 2021-10-14 |
EP2970291B1 (en) | 2022-05-11 |
SI2970291T1 (sl) | 2022-07-29 |
SG11201507595XA (en) | 2015-10-29 |
KR20150132172A (ko) | 2015-11-25 |
CA2901510A1 (en) | 2014-09-18 |
ES2924193T3 (es) | 2022-10-05 |
CA2901510C (en) | 2022-11-29 |
HRP20220628T1 (hr) | 2022-06-24 |
SG10201809696UA (en) | 2018-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20151652A1 (es) | Proceso e intermedios para preparar un medicamento | |
DOP2018000270A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
SV2017005587A (es) | Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen | |
DOP2017000304A (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
MY196328A (en) | New (Hetero)Aryl-Substituted-Piperidinyl Derivatives, A Process For Their Preparation And Pharmaceutical Compositions Containing Them | |
CL2015001307A1 (es) | Proceso para preparar profármacos nucleósidos. | |
CR20150370A (es) | Compuestos antivirales | |
CO7210068A1 (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CR20170590A (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CU24265B1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, útiles en el tratamiento del cáncer | |
UY34917A (es) | Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación | |
UY33950A (es) | Inhibidores de benzodioxano de la producciòn de leucotrieno | |
SG10201804021TA (en) | Methods of preparing inhibitors of influenza viruses replication | |
ECSP14026138A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
CR20180176A (es) | NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
BR112013025777A2 (pt) | imidazopiridazinas como inibidores da quinase akt | |
CO2018007278A2 (es) | Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan | |
CO2017003004A2 (es) | Nuevas triazolo[4,5-d]pirimidinas | |
ECSP15013883A (es) | Benzamidas | |
ECSP11010992A (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales | |
CR20180482A (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
BR112013003815A2 (pt) | derivados de carboxamida cílicos substituódos e derivados de ureia como ligantes do receptor vaniloide | |
DOP2016000009A (es) | Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
BR112013020841A2 (pt) | processo para preparar produtos que compreendem ativos estabilizados e composições que compreendem os mesmos |